Phase 3Active, not recruiting
A Phase 3 Study of NTLA-2001 in ATTRv-PN
MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)
- Sponsor
- Intellia Therapeutics (Industry)
- Enrollment
- 67 enrolled
- Conditions
- Neuromuscular Disease; Neuromuscular Diseases (NMD); Neurodegenerative Disease; Neurodegenerative Disease, Hereditary; Neurodegenerative Diseases; Neuromuscular Diseases; Nerve Disorders; Nervous System Disease; Nervous System Diseases; Genetic Disease, Inborn; Amyloidosis, Familial; Amyloidosis, Hereditary
- Interventions
- nexiguran ziclumeran; Normal Saline as Placebo
- Ages
- adults, older adults
- Registry
- NCT06672237
Full record on ClinicalTrials.gov
From the registry
This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.
Primary outcomes
- Modified Neuropathy Impairment Score +7 (mNIS+7)
- Serum TTR
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered